Cone snails have evolved a variety of insulin-like molecules that may help with the development of better treatments for diabetes.
The hormone insulin is produced by the pancreas and is important for regulating the sugar levels in the blood. Defects in the production or function of insulin can lead to type 1 or type 2 diabetes, which affect millions of people worldwide. The lives of many of type 1 diabetics are dependent on daily insulin injections, which is also necessary for many type 2 diabetic patients (Zaykov et al., 2016).
The key to effective insulin treatment is fast-acting drugs that can quickly deliver insulin to the target cells and mimic the way that the pancreas can regulate blood sugar levels. Natural insulin is first transported to the liver, where it inhibits the synthesis of glucose, and it only reaches the peripheral tissues later, where it eventually regulates the amount of glucose entering the cells.
However, insulin injections deliver the hormone directly to the periphery, which delays the inhibition of liver glucose production and causes fluctuations of blood sugar levels (Herring et al., 2014). Moreover, at high concentrations, insulin can form aggregates that take time to dissolve and consequently contribute to delaying its action after injection (Figure 1, upper panel; Baker et al., 1988). Developing faster treatments that are not prone to aggregation is a top priority, and although several fast-acting insulins are in clinical use, they still have not reached the same pharmacodynamics as natural insulin secreted by the pancreas (Herring and Russell-Jones, 2018; Zaykov et al., 2016).
Previous studies were able to identify the structure of the complex that insulin forms with its receptor, and the basics of how insulin binds to the receptor (De Meyts, 2015; Menting et al., 2013; Menting et al., 2014; Scapin et al., 2018; Weis et al., 2018). Now, in eLife, Helena Safavi-Hemami of the University of Utah School of Medicine and colleagues – including Peter Ahorukomeye and Maria Disotuar as joint first authors – report how cone snails could help progress our understanding of this process (Ahorukomeye et al., 2019).
Cone snails have evolved sophisticated strategies for hunting fish. They produce venomous, insulin-like molecules, which they release into the water to paralyze their victim (Figure 1, lower panel). The insulin-like molecules induce low blood sugar levels in their prey, which makes them unable to escape. It has previously been shown that the insulin-like peptide of a cone snail species does not form aggregates (Menting et al., 2016). Therefore, the researchers – who are based at institutes in the United States and Australia – wanted to find out if other cone snails also produced similar substances.
Ahorukomeye et al. discovered that although the species they analyzed made a range of different versions of these insulin-like peptides, none of the molecules could form aggregates. Moreover, the peptides were able to bind to human insulin receptors, and they were also effective in fish and mouse models of the disease, where they reversed high blood sugar levels. Structural and molecular analyses further revealed that the insulin-like peptides of the snails bind in an unusual way to the insulin receptor.
Previous research has shown that a region of insulin that is involved in the cluster formation, the C-terminus of the B chain, is also crucial for binding to the insulin receptor (Figure 1, upper panel; Baker et al., 1988; Menting et al., 2014). However, attempts to remove the B chain to avoid cluster formation have so far compromised the function of insulin.
Ahorukomeye et al. discovered that although the insulin-like peptides produced by the snails lacked the C-terminal part of the B chain, they could still effectively interact with the human insulin receptor. This might be because some their peptides contained hydrophobic amino acid residues that mimic important receptor-binding regions (e.g., phenylalanine at the position B24 of insulin) that had been lost with the missing C-terminal segment (Figure 1, lower panel). Moreover, these regions were very similar among the cone snail species studied. Taken together, these findings indicate that the C-terminus of the B chain is not necessary for insulin binding to the receptor. Future research may build on these results to design potent, fast-acting insulin agonists that are less likely to form aggregates.
The study of Ahorukomeye et al. highlights the beauty of evolution and the adaptability of organisms. We can learn important lessons from Nature as we seek to develop more patient-friendly insulin receptor agonists for the treatment of diabetes.
The structure of 2zn pig insulin crystals at 1.5 Å resolutionPhilosophical Transactions of the Royal Society of London B, Biological Sciences 319:369–456.https://doi.org/10.1098/rstb.1988.0058
A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulinNature Structural & Molecular Biology 23:916–920.https://doi.org/10.1038/nsmb.3292
The signalling conformation of the insulin receptor ectodomainNature Communications 9:4420.https://doi.org/10.1038/s41467-018-06826-6
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Fast-acting insulin found in certain sea snails could help us to design better diabetes treatments.
The Spike protein of SARS-CoV-2, its receptor binding domain (RBD), and its primary receptor ACE2 are extensively glycosylated. The impact of this post-translational modification on viral entry is yet unestablished. We expressed different glycoforms of the Spike-protein and ACE2 in CRISPR-Cas9 glycoengineered cells, and developed corresponding SARS-CoV-2 pseudovirus. We observed that N- and O-glycans had only minor contribution to Spike-ACE2 binding. However, these carbohydrates played a major role in regulating viral entry. Blocking N-glycan biosynthesis at the oligomannose stage using both genetic approaches and the small molecule kifunensine dramatically reduced viral entry into ACE2 expressing HEK293T cells. Blocking O-glycan elaboration also partially blocked viral entry. Mechanistic studies suggest multiple roles for glycans during viral entry. Among them, inhibition of N-glycan biosynthesis enhanced Spike-protein proteolysis. This could reduce RBD presentation on virus, lowering binding to host ACE2 and decreasing viral entry. Overall, chemical inhibitors of glycosylation may be evaluated for COVID-19.